HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation.

AbstractBACKGROUND:
Public Health England has reported a decrease of up to 20.8% in new diagnoses of external genital warts (GWs) among women aged <19 years since the national vaccination program with the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine began in 2008. A post hoc analysis of the phase III PATRICIA (PApilloma TRIal against Cancer In young Adults) trial (NCT00122681) was performed to ascertain whether protection against low-risk HPV types was apparent.
METHODS:
Vaccine efficacy (VE) at 48 months was assessed against 6-month persistent infection (6MPI) with low-risk HPV types in the total vaccinated cohort (TVC) and in the TVC naive (for 25 HPV types tested) populations.
RESULTS:
In the TVC naive cohort, VE against 6MPI (95% confidence interval) was 34.5% (11.3 to 51.8) for HPV-6/11, 34.9% (9.1 to 53.7) for HPV-6, 30.3% (-45.0 to 67.5) for HPV-11, and 49.5% (21.0 to 68.3) for HPV-74.
CONCLUSIONS:
The HPV-16/18 AS04-adjuvanted vaccine appears to have moderate efficacy against persistent infections with a number of low-risk HPV types (HPV-6/11/74), which are responsible for the majority of external GWs, and recently, antibody and cell-mediated immune response to HPV-6/11 have been observed. These findings may help to explain the decrease in external GW diagnoses seen in England.
AuthorsAnne Szarewski, S Rachel Skinner, Suzanne M Garland, Barbara Romanowski, Tino F Schwarz, Dan Apter, Song-Nan Chow, Jorma Paavonen, M Rowena Del Rosario-Raymundo, Julio C Teixeira, Newton S De Carvalho, Maria Castro-Sanchez, Xavier Castellsagué, Willy A J Poppe, Philippe De Sutter, Warner Huh, Archana Chatterjee, Wiebren A Tjalma, Ronald T Ackerman, Mark Martens, Kim A Papp, Jose Bajo-Arenas, Diane M Harper, Aureli Torné, Marie-Pierre David, Frank Struyf, Matti Lehtinen, Gary Dubin
JournalThe Journal of infectious diseases (J Infect Dis) Vol. 208 Issue 9 Pg. 1391-6 (Nov 01 2013) ISSN: 1537-6613 [Electronic] United States
PMID24092907 (Publication Type: Journal Article)
Chemical References
  • ASO4 mixture
  • Adjuvants, Immunologic
  • Lipid A
  • Papillomavirus Vaccines
  • Aluminum Hydroxide
Topics
  • Adjuvants, Immunologic (administration & dosage)
  • Aluminum Hydroxide (administration & dosage)
  • Clinical Trials, Phase III as Topic
  • Condylomata Acuminata (epidemiology, immunology, prevention & control)
  • Double-Blind Method
  • Female
  • Human papillomavirus 16 (immunology)
  • Human papillomavirus 18 (immunology)
  • Human papillomavirus 6 (immunology)
  • Humans
  • Incidence
  • Incidental Findings
  • Lipid A (administration & dosage, analogs & derivatives)
  • Multicenter Studies as Topic
  • Papillomavirus Vaccines
  • Randomized Controlled Trials as Topic
  • Treatment Outcome
  • Vaccination

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: